Trademark: 97095713
Word

Status
Pending
Status Code
686
Status Date
Tuesday, May 14, 2024
Serial Number
97095713
Mark Type
2
Filing Date
Wednesday, October 27, 2021
Published for Opposition
Tuesday, May 14, 2024

Trademark Owner History
Takeda Pharmaceutical Company Limited - Owner At Publication

Classifications
5 Pharmaceutical preparations for use in the field of autoimmunology, bacterial infection diseases and disorders, cardiology, central and peripheral nervous systems diseases and disorders, diabetes, endocrinology, haematology, hormonal diseases and disorders, gastroenterology, gout, immunology, infectious diseases and disorders, inflammatory diseases and disorders, musculoskeletal diseases and disorders, neuroscience, oncology, pain management, respiratory diseases and disorders, urological diseases and disorders, viral diseases and disorders, rare diseases namely, autoimmune rare diseases, bacterial infectious rare diseases, cardiological rare diseases, central and peripheral nervous systems rare diseases, diabetes rare diseases, endocrinological rare diseases, haematological rare diseases, hormonally originating rare diseases, gastroenterological rare diseases, gout rare diseases, infectious rare diseases, inflammatory rare diseases, musculoskeletal rare diseases, genetic rare diseases, neurological rare diseases, oncological cancer rare diseases, respiratory rare diseases, urological and kidney rare diseases, viral rare diseases; and pharmaceutical products and preparations containing plasma-derived therapies for treating immunodeficiencies, neuroimmunology, hematology, pulmonology, and rare diseases, namely, autoimmune rare diseases, bacterial infectious rare diseases, cardiological rare diseases, central and peripheral nervous systems rare diseases, diabetes rare diseases, endocrinological rare diseases, haematological rare diseases, hormonally originating rare diseases, gastroenterological rare diseases, gout rare diseases, infectious rare diseases, inflammatory rare diseases, musculoskeletal rare diseases, genetic rare diseases, neurological rare diseases, oncological cancer rare diseases, respiratory rare diseases, urological and kidney rare diseases, viral rare diseases; Pharmaceutical preparations in the field of vaccines, namely, vaccines for human use
The mark consists of a convex, weighted line situated above a smaller convex line, both positioned to frame an empty space.

Trademark Events
Oct 30, 2021
New Application Entered
Nov 9, 2021
New Application Office Supplied Data Entered
Nov 10, 2021
Notice Of Design Search Code E-Mailed
Nov 12, 2021
Teas Voluntary Amendment Received
Nov 12, 2021
Teas Amendment Entered Before Attorney Assigned
Aug 4, 2022
Assigned To Examiner
Aug 4, 2022
Non-Final Action Written
Aug 4, 2022
Non-Final Action E-Mailed
Aug 4, 2022
Notification Of Non-Final Action E-Mailed
Aug 4, 2022
Non-Final Action Written
Aug 4, 2022
Non-Final Action E-Mailed
Aug 4, 2022
Notification Of Non-Final Action E-Mailed
Jan 24, 2023
Teas Response To Office Action Received
Jan 24, 2023
Correspondence Received In Law Office
Jan 24, 2023
Teas/Email Correspondence Entered
Feb 22, 2023
Final Refusal Written
Feb 22, 2023
Final Refusal E-Mailed
Feb 22, 2023
Notification Of Final Refusal Emailed
Apr 14, 2023
Application Extension To Response Period - Received
Apr 14, 2023
Application Extension Granted/Receipt Provided
Jul 18, 2023
Teas Request For Reconsideration Received
Jul 18, 2023
Correspondence Received In Law Office
Jul 19, 2023
Teas/Email Correspondence Entered
Aug 22, 2023
Non-Final Action Written
Aug 22, 2023
Non-Final Action E-Mailed
Aug 22, 2023
Notification Of Non-Final Action E-Mailed
Oct 10, 2023
Teas Response To Office Action Received
Oct 10, 2023
Correspondence Received In Law Office
Oct 11, 2023
Teas/Email Correspondence Entered
Feb 26, 2024
Application Extension Granted/Receipt Provided
Nov 29, 2023
Subsequent Final Refusal Written
Nov 29, 2023
Subsequent Final Emailed
Nov 29, 2023
Notification Of Subsequent Final Emailed
Feb 26, 2024
Application Extension To Response Period - Received
Mar 5, 2024
Teas/Email Correspondence Entered
Apr 10, 2024
Approved For Pub - Principal Register
Apr 24, 2024
Notification Of Notice Of Publication E-Mailed
May 14, 2024
Published For Opposition
May 14, 2024
Official Gazette Publication Confirmation E-Mailed
Mar 5, 2024
Correspondence Received In Law Office
Mar 5, 2024
Teas Request For Reconsideration Received

Trademark Alertz updated from USPTO on 2030-01-24